Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Glioblastoma 41Glioma 10Brain Neoplasms 9Gliosarcoma 8Astrocytoma 7Neuroblastoma 6Small Cell Lung Carcinoma 4Oligodendroglioma 4Neoplasms 4Medulloblastoma 4Sarcoma, Ewing 3Sarcoma 3Melanoma 3Somatostatinoma 2Rhabdomyosarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Lung Neoplasms 2Ependymoma 2Diffuse Intrinsic Pontine Glioma 2Desmoplastic Small Round Cell Tumor 2Central Nervous System Neoplasms 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Supratentorial Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Prostatic Neoplasms 1

Interventions

Temozolomide 2Capecitabine 2Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Etoposide 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Somatostatinoma × Temozolomide × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡